Controlling pharmaceutical polymorphism in crystallization processes represents a major challenge in pharmaceutical science and engineering. For instance, CO 2 -antisolvent crystallization typically favors the formation of metastable forms of carbamazepine (CBZ), a highly polymorphic drug, with impurities of other forms. This work demonstrates for the first time that a supercritical CO 2 -antisolvent crystallization process in combination with certain molecular additives allows control of the polymorphic outcome of carbamazepine. We show herein that in the presence of sodium stearate and Eudragit L-100, needle-shaped crystals of CBZ form II are obtained, while blocky-shaped crystals of CBZ form III are obtained in the presence of Kollidon VA64, sodium dodecyl sulfate, ethyl cellulose and maltitol. This selectivity for pure forms in this supercritical set up contrasts to the results when the same set of additives where used in a solvent evaporation method that yielded mixtures of form I, II and III. The type of additive used in the CO 2 -antisolvent crystallization process impacted both the product crystals polymorphic form and size. A detailed molecular-level analysis along with DFT calculations allowed us to give a mechanistic insight into the role of sodium stearate and Eudragit L-100 in facilitating nucleation of the metastable form II.
Introduction
The ability of an API (Active Pharmaceutical Ingredient) to crystallize or interconvert into distinct polymorphic forms during processing or shelf life has emerged as a major concern for the pharmaceutical industry [1, 2] . As polymorphism is one of the key controlling factors directly impacting the processability of a drug substance and the quality, safety and efficacy of a drug product, there is an ever increasing need to both understand and control pharmaceutical crystallization processes.
Polymorphism is influenced by several factors including processing conditions such as temperature, pressure, type of solvent and antisolvent, supersaturation and the presence of molecular additives or impurities [3, 4] . The use of additives in pharmaceutical crystallization is of high importance particularly to the industry due to their ability to favor the nucleation and crystal growth of a particular crystalline form with the desired physicochemical properties, while inhibiting the formation of another crystalline form [5, 6] . Molecules of an additive may potentially be incorporated into the crystal lattice of an API and influence its crystallization processes [7] . Some publications have highlighted the ability of different types of impurities or additives to not only influence the polymorphic outcome in a crystallization process but also the crystals morphology and size [8] [9] [10] [11] . However, the mechanisms involved in the additive-mediated crystal growth and polymorphic transformations are still unknown in many cases.
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Conventional crystallization techniques such as cooling crystallization or solvent evaporation have the disadvantage of providing slow nucleation and crystal growth kinetics, taking a long time to produce crystals. However, these methods may potentially favor the formation of more stable polymorphic forms instead of metastable ones and typically generate larger crystals [12] . Antisolvent techniques, which consist of adding a non-solvent to a saturated solution to induce the precipitation of the solute, provide much faster nucleation and crystallization kinetics, typically favoring the formation of metastable polymorphic forms and smaller crystals [13] [14] [15] . Water is typically used as an antisolvent for the crystallization of poorly-soluble APIs. However, when using water as a liquid antisolvent the final suspension needs to be filtered and dried or directly spray-dried to obtain the final powder, and depending on API used there is the risk of forming a hydrate during processing [16] [17] [18] . Using supercritical CO 2 as the antisolvent there is no risk of forming hydrates [19] and the remaining organic solvent is removed from the final product during flushing with CO 2 after the crystallization process, providing a solvent-free dried product [20, 21] .
CBZ, a first generation anticonvulsant used in the treatment of epilepsy and trigeminal neuralgia, is an interesting model system for the study of crystallization processes due to its ability to generate distinct solid state forms such as polymorphs, hydrates, salts and cocrystals. CBZ exists in at least four anhydrous polymorphs (I, II, III and IV), with form III being the most stable polymorph under ambient conditions. The literature provides some examples on the crystallization of CBZ polymorphs by traditional crystallization methods such as cooling crystallization and solvent evaporation, including the use of additives or functionalized templates aiming to control the final polymorphic form obtained [22] [23] [24] [25] [26] . However, these methods provide slow crystallization kinetics and require the use of additional filtration and drying steps to remove the residual organic solvent from the final particles. CBZ crystals have been also produced using supercritical CO 2 antisolvent method, however the samples obtained in that study represented mixtures of several metastable 5 polymorphic forms (I, II) with some impurities from form III [27] . To the best of our knowledge there has been no systematic study published in the literature which: (i) addresses the use of CO 2 antisolvent methods to successfully obtain distinct PXRD-pure polymorphic forms of CBZ, and (ii) addresses the use of molecular additives in CO 2 antisolvent methods to provide control over the CBZ polymorphic form obtained.
This paper aims to answer the following questions: is it possible to control the polymorphic outcome of CBZ by using molecular additives in a supercritical CO 2 antisolvent crystallization process?
Which mechanisms are involved between solvent, API and additive molecules in a CO 2 antisolvent method for favoring the formation of a particular polymorph whilst inhibiting the formation of another?
In this work a gas antisolvent (GAS) process is used to crystallize distinct carbamazepine (CBZ) polymorphs from methanol solutions containing molecular additives. The results are compared with those obtained using a traditional crystallization process (solvent evaporation). A detailed analysis of the relevant CBZ crystal structures along with molecular modelling using Density Functional Theory (DFT) have been applied in order to gain insight into molecular mechanisms by which the additives govern the polymorphic outcome of CBZ.
Experimental Section

Materials
Carbamazepine (verified to be Form III by reflection powder X-ray diffraction), sodium stearate, Pluronic F-127, sodium dodecyl sulfate, ethyl cellulose, Polysorbate 80, PVP360, PEG 400 and HPMC were purchased from Sigma Aldrich and used without further purification (purity was >99.9%). Kollidon VA 64 was obtained from BASF, PEG 3400 was obtained from Polysciences and HPC (Klucel) was obtained from Ashland. Eudragit L-100, Eudragit L-100-55 and Eudragit EPO 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   6 were a generous gift from Evonik Industries. Carbon dioxide (99.98%) was supplied by BOC (Ireland). Table 1 summarizes the different types of additives used in this work. Table 1 -Type of additives used in the preparation of carbamazepine solutions in methanol for gas antisolvent (GAS) and/or solvent evaporation (SV) processing.
SDS: Sodium Dodecyl Sulfate; PVP: Polyvinylpyrrolidone; HPMC: Hydroxypropylmethylcellulose; HPC: Hydroxypropylcellulose; PEG: Polyethylene Glycol.
Solution preparation
Carbamazepine (CBZ) with/without additives was dissolved in methanol (70.0 mg in 1 mL of methanol) using moderate shaking with a vortex and ultrasonic treatment (~5 min). When using additives for the preparation of the CBZ solutions, 5% w/w (~4.0 mg) of each additive were dissolved in the CBZ solutions. The solutions were then filtered through a 0.2 µm pore size nylon filter (Whatman Inc., Florham Park, NJ) to remove any undissolved material. Table 2 shows the experimental conditions used in the preparation of the CBZ solutions prior being processed by gas antisolvent (GAS) or solvent evaporation (SV). The GAS and SV experiments were performed three times, except for the experiments where pure polymorphs II or III of carbamazepine have been Kollidon VA64  -PVP360   ---PEG 400   ---PEG 3400 7   obtained (GAS 2, 4, 7, 8, 9 and 10 -see Table 3 ) which were performed at least 6 times. 8 Figure 1 shows a schematic diagram of a custom-built batch gas antisolvent (GAS) apparatus. It consists essentially of a 100 cm 3 stainless steel storage vessel and a 10 cm 3 stainless steel highpressure vessel (where the crystallization experiments take place) with monitored temperature and pressure using a T-type thermocouple and a pressure transducer (Omega model PX603), respectively. These vessels are placed inside a temperature-controlled air chamber. A borosilicate window was placed over the top of the high-pressure vessel for visualization purposes during the experiments.
Gas antisolvent crystallization (GAS)
Figure 1 -Schematic diagram of the batch supercritical antisolvent apparatus. 1, gas cylinder; 2, gas compressor; 3, back-pressure controller; 4, gas storage vessel; 5, high-pressure vessel; 6, magnetic stirrer.
A Teledyne ISCO 260D pump was used to load the CO 2 into the storage vessel before being introduced into the high-pressure vessel. A solution containing 70 mg of CBZ dissolved in 1mL of methanol with/without an additive was placed inside the high-pressure vessel and compressed with 9 CO 2 up to the desired pressure and temperature until crystallization takes place. During the addition of CO 2 , the solutions were subjected to magnetic stirring at 300 rpm to improve the mixing between the CO 2 and the solution. When supersaturation is reached and crystallization takes place, magnetic stirring is turned off and the valve which links to the vent is opened to continuously flush supercritical CO 2 through the high-pressure vessel out to the vent (in order to remove the methanol from the samples). CO 2 was flushed through the high-pressure vessel during 1 hour at a flow-rate of approximately 10ml/min. After flushing was completed, the high-pressure vessel was slowly depressurized and the resulting material was collected.
The samples obtained from the experiments were stored in a closed desiccator prior to its characterization.
Solvent evaporation (SV) crystallization
According to Table 2 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 10 Scanning Electron Microscopy (SEM) was performed using a JEOL Carryscope scanning electron microscope JCM-5700. Samples were mounted onto aluminum stubs with carbon tabs and coated by an ultrathin gold layer prior to analysis.
Raman spectra of solid samples were collected using a Kaiser Raman Rxn2 analyzer with an
Invictus 785 nm excitation laser and a CCD camera-based detector. A noncontact half-inch probe was used and each spectrum was collected for a minimum of 30 s exposure time and six accumulations in the region of 3400 cm -1 to 100 cm -1 using Mettler Toledo iC Raman software version 4.1.
Crystal size distributions were obtained by analyzing images obtained from a Zeiss optical microscope using the ImageJ software.
Molecular modelling
Density functional theory (DFT) calculations were applied using a Gaussian 09 package [28] to investigate strength of interaction between molecules forming (1:1) associates (dimers) of sodium stearate-methanol and sodium dodecyl sulfate-methanol at the polar 'heads' of the surfactants, and sodium stearate-CBZ and sodium dodecyl sulfate-CBZ at both the polar 'heads' and the non-polar 'tails' of the surfactants. In addition (1:1) binding interactions are quantified for CBZ-CBZ, CBZacetic acid, CBZ-methanol, and CBZ-CO 2 associates. The equilibrium geometries (gas-phase) are calculated with a B97-D3 Grimme's functional [29] , and a Gaussian-type 6-31G(d,p) basis set [30] .
The (1:1) binding energy in a dimer is calculated as follows: 
Where E AB is the energy of a dimer AB and E A and E B are energies of the isolated molecules A and B, both being in fully relaxed gas-phase geometries. The DFT energies are calculated using a double hybrid B2PLYP-D3 functional [31] , which combines exact Hartree-Fock exchange with an MP2-like correlation and long-range dispersion corrections; here we use a basis set of quadruple-ζ valence quality (def2-QZVPP) [32] . This methodology has been successfuly applied for small and mediumsized API molecules in recent nucleation studies on salicylic acid [33] , parabens [34] , and
The molecular structures were visualized using Materials Studio 7.0 from Accelrys Inc. Table 2 shows the experimental conditions used for the preparation and processing of carbamazepine solutions by GAS and SV methods, while Table 3 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Table 3 -List of carbamazepine (CBZ) solid forms obtained using gas antisolvent (GAS) and solvent evaporation (SV) methods. For GAS experiments pressure was 90 bar, temperature was 40ºC, magnetic stirring rate was 300 rpm and CO 2 addition rate was 1.52 g/s. Ratio of additive to total solids (CBZ + additive) used in GAS and SV experiments was 5 % (w/w). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   13 Figure 2 -Powder X-ray diffraction patterns of distinct CBZ polymorphic forms (I, II and III) from CSD (Cambridge Structural Database), raw CBZ and CBZ samples produced by the GAS (GAS 1) and SV (SV 1) methods without using additives.
Results and Discussion
Crystallization of carbamazepine (CBZ) by gas antisolvent (GAS) and solvent evaporation (SV)
Due to the difficulties in obtaining pure polymorphic forms of CBZ from methanol solutions in preliminary experiments (GAS 1 and SV 1) using either GAS or SV methods, distinct types of excipients/additives were selected (Table 1 ) and dissolved together with CBZ in methanol for the GAS experiments (GAS 2 to 16 listed in Tables 2 and 3 ) in order to assess their impact on the final polymorphic form of CBZ. Table 3 lists the CBZ polymorphic forms which have been obtained by GAS using the different additives. Interestingly, the GAS experiments, in which sodium stearate (GAS 2) and Eudragit L-100 (GAS 4) were used as additives, yielded PXRD pure CBZ form II. In contrast, PXRD pure CBZ form III was obtained when using Kollidon VA64 (GAS 7), sodium 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 dodecyl sulfate (GAS 8), ethyl cellulose (GAS 9), and maltitol (GAS 10). These experiments were repeated at least 6 times and provided a high reproducibility on the final CBZ polymorphic form obtained (100% The additives which provided pure polymorphic forms of CBZ by GAS were further used in the SV experiments for comparison purposes. Figure 3 shows the PXRD patterns for all GAS experiments respectively (experimental conditions used in these experiments are listed in Tables 2 and 3 ).
Although the different polymorphs feature a number of distinct peak positions and intensities, the most characteristic for the identification of form II is the peak appearing at ca. 5º (2 Theta) in a PXRD diffractogram. 15 Figure 3 -Powder X-ray diffraction patterns of distinct CBZ polymorphic forms (I, II and III) from CSD (Cambridge Structural Database) and CBZ samples produced by the GAS method (GAS 1 to 16). Figure SI1 in the Supporting Information shows that, using the same set of additives as used in GAS, no pure polymorphs were obtained in the SV experiments. This is in contrast to the GAS experiments, where either pure form II or form III was observed in certain cases (see Table 3 ).
Noteworthy, the GAS method provides much faster crystallization times than the SV process. Using a CO 2 addition rate of 1.52 g/s the pressure inside the high-pressure vessel goes from 1 bar to 90 bar in approximately one second, inducing the precipitation of CBZ crystals during that time frame. As supercritical CO 2 has a good miscibility with many organic solvents including methanol, it easily dissolves in the methanol solution during the crystallization step. Subsequently, the CO 2 antisolvent removes the methanol from the high-pressure vessel during a flushing step. As a result, the CBZ particles have progressively less and less methanol molecules in their surroundings. If the polymorphic transformation to form III is solvent-mediated [36], this could be another argument (besides the kinetic factor) explaining why the GAS method does not yield the form III crystals.
Taking into account that the processing parameters in the GAS method are the same in all the experiments, it appears that the observed pure CBZ form II being obtained in the presence of sodium stearate and Eudragit L-100 results from the efficient promotion and stabilization of the metastable form II by these two particular additives. Notably, in presence of these two particular excipients, the form II appears in the crystallization mixture as well when using the SV method. This suggests that, regardless of the crystallization method, the CBZ form II crystals can form only if sodium stearate or Eudragit L-100 is present in the crystallization solution.
Particle size and shape of CBZ crystals produced by GAS Figure 4 shows SEM images of selected CBZ samples produced by the GAS method (see Table 2 ). Figure 4 -Scanning Electron Microscopy images of CBZ crystals produced from different GAS runs: (a) GAS 1; (b) GAS 15; (c) GAS 2; (d) GAS 4; (e) GAS 7; (f) GAS 8; (g) GAS 9; (h) GAS 10. 
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The SEM analysis corroborates the PXRD results. The CBZ samples which contain mixtures of CBZ forms II and III (e.g. GAS 1 (no additives) and GAS 15 (PEG 400)) are composed of intermixed particles: needles (form II) and block-shaped (form III) particles (Figs. 4a and 4b, respectively). In contrast, the CBZ samples crystallized with sodium stearate (Fig. 4c, GAS 2) and Eudragit L-100 (Fig. 4d, GAS 4) as additives, show needle/rod shaped particles only, being characteristic of the CBZ form II. On the other hand, CBZ crystallized in presence of Kollidon VA 64 (Fig. 4e, GAS 7) , SDS (Fig. 4f, GAS 8 ), Ethyl Cellulose (Fig. 4g, GAS 9 ), and Maltitol ( The most pronounced differences in the distribution of particle sizes have been observed for the blocky crystals of form III generated with the GAS method. In order to assess an impact of the additive type on the crystal size distributions we have employed image analysis (Fig. SI2 in the Suppporting Information). It appears that CBZ particles produced in presence of SDS (GAS 8) had smaller sizes with relatively narrow size distribution. On the other hand, the largest CBZ crystals with broadest size distribution were produced with Maltitol (GAS 10).
Molecular-level analysis
A carbamazepine molecule has amphiphilic character as its one part features polar groups (carbonyl, C=O, and amide, NH 2 ), which are capable of forming strong H-bonds, while the other part is predominantly hydrophobic, being made of three conjugated hydrocarbon rings. Two CBZ molecules tend to form a symmetric dimer through double C=O … H-N H-bonding. Interestingly, such a dimer is a building block (a synthon) present in all the three polymorphs (Fig. 5) . It is commonly accepted that hydrogen bonds formed between polar groups are strong and directional, in contrast to much weaker and less directional interactions of non-polar hydrocarbon hydrogens. Thus the strongest interactions in all the three crystal lattices are actually those between the two molecules (Fig. 5) .
A feature which distinguishes form II from the other two polymorphs is the presence of empty channels with a diameter of ca. 7 Å, being parallel to the crystallographic c-axis. The walls of the channels are made of non-polar rings of CBZ molecules; this is an interesting feature which will further be discussed in relation to the question why the polymorph II nucleates in the presence of particular polymeric additives. Our computationally-derived models show that the columnar stacking arrangement of the dimers as observed in form I and form II crystals leads to elongated rod-like particles, while the non-columnar orientation of CBZ molecules results in a blocky-shaped particle (Fig. 6) . The predicted rod-like particles of form I and form II crystals and the blocky particles of form III crystals closely match the experimentally-observed morphologies of form I and form II (elongated rods/needles) and form III (blocks) [36] . Thus, it appears that at the employed experimental conditions the shape analysis of the crystalline particles can be used to distinguish form III from the other two polymorphs.
When looking at the polymeric additives that lead to nucleation of either form II or form III (Fig. 7) , it is difficult to find any common structural factor which could explain why one set of polymers lead to a particular polymorph. This suggests that, among the additives studied, there is probably more than one mechanism to govern the nucleation of CBZ into a particular polymorph. The structural complexity and size of polymeric additives makes molecular modelling very challenging. For this reason, in our modelling work we have focused on two surfactants which lead to distinct polymorphs of CBZ: sodium stearate (form II promoter) and sodium dodecyl sulfate (form III promoter). Figure 7 -Structural details of the polymeric additives which promote the formation of either pure carbamazepine form II or form III when using a gas (supercritical CO 2 ) antisolvent crystallization process.
Sodium stearate consists of a hydrocarbon tail (17-carbon) and a sodium carboxylate end (COO -Na + ), while sodium dodecyl sulfate consists of a 12-carbon tail attached to a sodium sulfate end (SO 4 -Na + ). Our DFT calculations indicate that both CBZ and methanol interact stronger with the sodium sulfate part of the SDS molecule as compared to weaker binding to the COO -Na + group of sodium stearate (Fig. 8) . The possible reason can be that in the case of SDS, the amine hydrogen of the CBZ molecule (H-bond donor) interacts with two oxygens of the SO 4 group, whereas in sodium stearate there is only one carboxylic oxygen, which is involved in the bonding. surfactant-CBZ > CBZ-CBZ > CBZ-methanol. This suggests that the CBZ dimers might preferentially form in the presence of methanol (but in the absence of surfactant). However, if surfactant is present, the formation of the surfactant-CBZ complex would be energetically more preferential over both the CBZ-CBZ and CBZ-methanol dimers.
In the GAS process, carbon dioxide is being used as antisolvent. It is well known that, due to its nonpolar nature, CO 2 molecules are incapable of forming strong intermolecular bonds. This is clearly reflected in the lowest binding energy (-11.4 kJ/mol) calculated for the CBZ-CO 2 associate (Fig. 8) .
It seems that the low interaction strength makes the CO 2 molecules fairly inert and non-competitive towards interactions with polar sites of CBZ, in contrast to much stronger interacting molecules of methanol and surfactants. If looking at polar 'heads' of the two surfactants it appears that the sulfonyl group in SDS contains four oxygen atoms capable of interacting with the amine protons of CBZ, compared to two oxygens present in the sodium stearate carboxylic group. Accordingly, SDS can potentially bind to at least three CBZ molecules, while sodium stearate can make a strong bonding with maximum two CBZ molecules. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Figure 8 -DFT binding energies calculated for (1:1) molecular associates of sodium stearatecarbamazepine (CBZ), sodium stearate-methanol, sodium dodecyl sulfate-CBZ, sodium dodecyl sulfate-methanol, CBZ-CBZ, CBZ-acetic acid, CBZ-methanol, and CBZ-CO 2 . Calculations performed at B97-D3/6-31G(d,p) level (geometry) and B2PLYP-D3/def2-QZVPP level (energy). Carbon -grey, hydrogen -white, nitrogen -blue, oxygen -red, sulfur -yellow, sodium -purple.
As expected, the aliphatic 'tails' of both the surfactants exhibit significantly weaker interactions with the non-polar parts of the CBZ molecule, ranging from -0.6 kJ/mol to -7.5 kJ/mol ( Figure 9 ). Our calculations also show that the perpendicular orientation of the CBZ-surfactant pair yields relatively stronger binding energy than the parallel stacking of the molecules. In the latter case the binding 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 25 strength of the CBZ molecule to SDS and to sodium stearate is comparable (7.0 kJ/mol vs 7.5 kJ/mol). Figure 9 -DFT binding energies calculated for (1:1) molecular associates of sodium stearate-carbamazepine (CBZ) and sodium dodecyl sulfate-CBZ with parallel (top) and perpendicular (bottom) orientation of the molecules. Calculations performed at B97-D3/6-31G(d,p) level (geometry) and B2PLYP-D3/def2-QZVPP level (energy). Carbon -grey, hydrogen -white, nitrogen -blue, oxygen -red, sulfur -yellow, sodium -purple.
In solution the surfactant molecules are expected to exhibit some conformational freedom, thus we have also estimated the interaction strength of the CBZ molecules with bent conformations of the surfactants. While fully bent, the surfactants expose both their polar and non-polar parts towards interaction with the CBZ molecule, and the resulting binding strength is substantially higher for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 26 sodium dodecyl sulfate (-28.4 kJ/mol) than for sodium stearate (-17.5 kJ/mol) (Fig. SI3 in the Supporting Information).
Taking into account the above considerations and the fact that it is not SDS (12-carbon tail) but sodium stearate (17-carbon tail) that promotes nucleation of polymorph II, it appears that the sufficient length of the hydrocarbon chain may be one of the key structural parameters of a surfactant to efficiently template the nucleation of form II. Another factor may be the interaction strength and the number of solute molecules (CBZ) bound to the ionic part of a surfactant. It seems sensible to expect that more solute molecules strongly bound to the ionic 'head' of the SDS surfactant would create greater steric hindrance and would disturb other CBZ molecules from potentially templating on the hydrocarbon backbone more than it would be in the case of sodium stearate. Also, the significantly higher binding strength of the CBZ molecule to the bent conformation of SDS suggests that in solution the availability of this surfactant in its linear conformation (which appears to be the preferred conformation to template channels and columns of the Form II crystal) may be lower than in the case of sodium stearate.
A possible mechanism of the surfactant-templated nucleation of CBZ form II is proposed in Figure   10 .
27 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 28 groups (hydrophilic) and ester groups (predominantly hydrophobic) (see Fig. 7 ). Our DFT computations show that a CBZ molecule can bind by 9 kJ/mol stronger to carboxylic group of acetic acid (∆E bind = -63.3 kJ/mol) than to another CBZ molecule (∆E bind = -54.3 kJ/mol) (see Fig. 8 ). This suggests that CBZ molecules may preferentially bind to the carboxylic groups of the polymer, instead of forming CBZ-CBZ dimers. This could result in alignment of the CBZ molecules alongside the polymer's linear chain, which seems to be a prerequisite for the formation of channels and columns of CBZ dimers as present in the crystal lattice of form II.
Besides the proposed hypothesis of templating and stabilizing the metastable Form II at the nucleation stage (using sodium stearate or Eudragit L-100), the appearance of the Form II may alternatively result from the inhibiting effect of sodium stearate and Eudragit L-100 on the polymorphic transition of the already formed metastable Form II crystals. Thus the Oswald's rule of stages, which postulates transformation to the more stable Form III, could not be followed in presence of these two additives.
Conclusions
It has been demonstrated that the polymorphic outcome of carbamazepine (CBZ) can be controlled when using a CO 2 -antisolvent crystallization method in combination with a certain additive type. In contrast, when using the same set of the additives, a solvent evaporation method provided mixtures of different polymorphs. Our SEM and PXRD results showed unanimously that sodium stearate and Eudragit L-100 as additives favor formation of needle-shaped crystals of CBZ form II, whereas KVA64, SDS, ethyl cellulose, and maltitol lead to formation of blocky-shaped crystals of CBZ form III.
A molecular-level analysis revealed that the specific packing of the columns in the form II crystal results in formation of empty channels featuring hydrocarbon-terminated (hydrophobic) walls. We 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   29 propose that the specific arrangement of columns and channels of the form II crystal would emerge in the nucleation process due to conjunction of the non-polar parts of CBZ molecules with the nonpolar tail of a surfactant. Another additive leading to formation of pure polymorph II is Eudragit L-100. Our DFT calculations show that carboxylic groups, which are present in the linear polymeric backbone of Eudragit L-100, exhibit stronger binding to CBZ molecules as compared to the CBZ-CBZ dimer (being present in all the three polymorphs). This suggests that, through its carboxylic groups, Eudragit L-100 may form relatively stable complexes with the CBZ molecules, which if aligned, could facilitate columnar arrangement -a feature of the CBZ form II crystal.
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Carbon -grey, hydrogen -white, nitrogen -blue, oxygen -red, sulfur -yellow, sodium -purple. Tables   Table 1 -Type of additives used in the preparation of carbamazepine solutions in methanol for gas antisolvent (GAS) and/or solvent evaporation (SV) processing. Table 2 -Experimental conditions used in the preparation of carbamazepine solutions in methanol for gas antisolvent (GAS) and solvent evaporation (SV) methods. For GAS experiments pressure was 90 bar, temperature was 40ºC, magnetic stirring rate was 300 rpm and CO 2 addition rate was 1.52 g/s. Ratio of additive to total solids (CBZ + additive) used in GAS and SV experiments was 5 % (w/w). Table 3 -List of carbamazepine (CBZ) solid forms obtained using gas antisolvent (GAS) and solvent evaporation (SV) methods. For GAS experiments pressure was 90 bar, temperature was 40ºC, magnetic stirring rate was 300 rpm and CO 2 addition rate was 1.52 g/s. Ratio of additive to total solids (CBZ + additive) used in GAS and SV experiments was 5 % (w/w). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   34   For Table of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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